X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application for Mavorixafor - licenced to Norgine for commercialisation in Europe.
Published on 08/07/2025 at 18:06 |
prnewswire.co.uk
Norgine Germany Switzerland Netherlands United Kingdom France Italy Spain Austria Belgium United States of America
